Correspondingly, a body of findings, gathered over decades, has suggested the activation of plasmin by urikinase-type plasminogen activator as a hallmark of metastatic and therapy-resistant breast cancer, although the underlying mechanisms connecting plasmin activity to metastatic breast cancer might be a little subtle50. Here, PLG is linked to breast carcinoma.